Skip to main content
IntegraGen logo

IntegraGen — Investor Relations & Filings

Ticker · ALINT ISIN · FR0010908723 LEI · 969500CQD8K0BUIGDH55 PA Professional, scientific and technical activities
Open in API
Filings indexed 160 across all filing types
Latest filing 2020-09-18 Earnings Release
Country FR France
Listing PA ALINT

About IntegraGen

https://integragen.com/

IntegraGen, an OncoDNA company, specializes in translating molecular research into clinical practice, with a primary focus on cancer genomics and rare genetic diseases. The company provides comprehensive genomic services, including Next-Generation Sequencing (NGS) and advanced bioinformatics analysis, to academic researchers, biopharmaceutical companies, and clinical research organizations. Operating from a CLIA/CAP-certified laboratory, IntegraGen is a key genomics partner for oncology clinical trials. Its core mission involves identifying novel genetic biomarkers to develop and commercialize molecular diagnostic tests, delivering interpretable genomic data to advance both research and patient care.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 100% confidence The document is titled "COMMUNIQUE DE PRESSE - DIFFUSION IMMEDIATE" and presents the financial results for the first half (S1) of 2020, including key figures like revenue, EBITDA, EBIT, and a balance sheet as of June 30, 2020. This structure—a press release detailing period-specific financial performance (half-year results) with key metrics and management commentary—is characteristic of an Earnings Release (ER). While it contains detailed financial tables, its format as an immediate press release announcing the results, rather than the comprehensive, formally filed report (like an IR or 10-K), points towards ER. It is not a full Interim/Quarterly Report (IR) which is typically more extensive and formally structured, nor is it a Call Transcript (CT) or Investor Presentation (IP). H1 2020
2020-09-18 French
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités de mise à disposition de la note d'information visée ou de la note en réponse visée
Report Publication Announcement Classification · 95% confidence The document is a short announcement (3309 characters) regarding the availability of a 'Note en Réponse' (Response Document) related to a public tender offer (Offre Publique d'Achat) initiated by OncoDNA for Integragen shares. It explicitly states that the response document and related financial/legal information have been filed with the AMF and are now available to the public on websites. Following the 'Menu vs Meal' rule, this is an announcement of a report/filing rather than the report itself, fitting the definition of a Report Publication Announcement (RPA).
2020-09-16 French
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités de mise à disposition de la note d'information visée ou de la note en réponse visée
M&A Activity Classification · 98% confidence The document is titled "OFFRE PUBLIQUE D'ACHAT VISANT LES ACTIONS DE LA SOCIETE INTEGRAGEN SA INITIEE PAR LA SOCIETE ONCODNA S.A." (Public Takeover Bid targeting the shares of Integragen SA initiated by OncoDNA S.A.). It specifically mentions the 'COMMUNIQUE DE MISE A DISPOSITION DE LA NOTE D'INFORMATION' (Press release regarding the availability of the Information Memorandum) and references regulatory filings with the AMF (Autorité des marchés financiers). This clearly indicates an announcement related to a takeover bid or merger activity. Based on the provided definitions, the most appropriate category is 'M&A Activity' (Code: TAR). The document is a press release announcing the availability of offer documents, not the full offer document itself, but the core subject matter is M&A.
2020-09-16 French
News releases during takeover bids / Takeover bids Other news releases
Major Shareholding Notification Classification · 99% confidence The document explicitly discusses a 'friendly takeover bid' by OncoDNA on IntegraGen SA, mentioning the filing of a draft offer with the French Autorité des Marchés Financiers (AMF) and the acquisition of shares leading to a 29.99% holding. This content directly relates to merger proposals and takeover activities. Therefore, the appropriate classification is 'M&A Activity' (TAR). The document is a substantive announcement, not just a notice of publication.
2020-08-13 English
Communiqués publiés en période d'offre publique d'acquisition / OPA Autres communiqués
M&A Activity Classification · 98% confidence The document discusses an amicable public takeover bid (offre publique d'achat amicale) by OncoDNA for IntegraGen SA. It mentions the filing of the offer project with the Autorité des Marchés Financiers (AMF) and the acquisition of shares leading up to this bid. This activity directly relates to a merger or takeover proposal. Based on the definitions, the category 'M&A Activity' (Code: TAR) is the most appropriate fit for announcements concerning merger proposals or takeover bids.
2020-08-13 French
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Transaction in Own Shares Classification · 95% confidence The document is titled "BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE" (Semi-annual balance sheet of the liquidity contract) and details the status of a liquidity contract managed by Oddo Corporate Finance for IntegraGen S.A. as of June 30, 2020. It reports the number of shares and cash balance in the liquidity account, as well as transactions executed during the first half of 2020 (01/01/2020 to 30/06/2020). This type of report, detailing transactions related to share buybacks or maintenance of market liquidity, directly corresponds to the definition of 'Transaction in Own Shares' (POS), which covers share repurchase/issuance activities, or potentially a specific financing/capital activity. Given the focus on the liquidity contract (often used for share stabilization or repurchase programs), 'POS' (Transaction in Own Shares) is the most precise fit among the provided options, as it relates to the company's interaction with its own stock via a designated agent. It is not a general earnings release (ER) or an interim report (IR), but a specific regulatory disclosure related to market operations.
2020-07-10 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.